Anika Therapeutics Inc
$ 21.42
6.25%
07 Aug - close price
- Market Cap 269,801,000 USD
- Current Price $ 21.42
- High / Low $ 21.55 / 20.09
- Stock P/E N/A
- Book Value 10.26
- EPS -0.24
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.02 %
- 52 Week High 21.55
- 52 Week Low 7.92
About
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$21.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-29 | 2026-04-29 | 2026-02-26 | 2025-11-05 | 2025-07-30 | 2025-05-09 | 2025-03-12 | 2024-10-31 | 2024-08-08 | 2024-05-08 | 2024-03-13 | 2023-11-02 |
| Reported EPS | 0.3 | 0.27 | 0.13 | -0.17 | -0.13 | -0.06 | -0.14 | -0.25 | 0.17 | 0.09 | -4.3 | -0.45 |
| Estimated EPS | -0.19 | -0.16 | -0.19 | -0.19 | -0.13 | 0.09 | -0.11 | 0.3 | 0.2 | 0.05 | -0.26 | -0.35 |
| Surprise | 0.49 | 0.43 | 0.32 | 0.02 | 0 | -0.15 | -0.03 | -0.55 | -0.03 | 0.04 | -4.04 | -0.1 |
| Surprise Percentage | 257.8947% | 268.75% | 168.4211% | 10.5263% | 0% | -166.6667% | -27.2727% | -183.3333% | -15% | 80% | -1553.8462% | -28.5714% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANIK
2026-08-06 12:10:19
Anika Therapeutics director Gary P. Fischetti purchased a total of 2,000 shares of the company's common stock through open-market transactions on August 3 and 4, 2026. The purchases were made at per-share prices of $20.745 and $20.315, respectively. Following these transactions, Fischetti directly holds 54,015 shares of Anika Therapeutics common stock.
2026-08-04 07:40:16
Anika Therapeutics Inc. (ANIK) reported mixed results for Q1 2025, with commercial channel revenue up 18% and regenerative solutions growing 33%, driven by the Integrity implant system. Strategic initiatives and cost-saving measures proved effective, with anticipated US approvals for Halofast and Singal expected to boost future performance. However, overall revenue declined 10% due to a 23% drop in the OEM channel from pricing pressure on Monovik and Orthovisk, leading to a 9-percentage-point decrease in gross margin and manufacturing challenges.
2026-08-01 20:40:16
This article reports on Anika Therapeutics' significant stock gain of 29%. The rise in stock price has benefited company insiders who engaged in recent trades.
2026-07-31 14:11:02
Vanguard Capital Management LLC has reported a 4.95% beneficial ownership stake in Anika Therapeutics Inc (ANIK), amounting to 659,216 shares as of June 30, 2026. The filing indicates that Vanguard holds sole voting power over 87,103 shares and sole dispositive power over all 659,216 shares, with no shared voting or dispositive power. This investment reflects holdings across Vanguard funds and managed accounts, with no single other person having an interest exceeding 5% through these securities.
2026-07-31 08:09:43
B. Riley has increased its price target for Anika Therapeutics (NASDAQ: ANIK) to $21 from $18, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook from the analyst firm regarding the company's future performance.
2026-07-30 15:41:19
B. Riley has increased its price target for Anika Therapeutics (ANIK) to $21 from $18, while reaffirming its Buy rating on the stock. This adjustment reflects a positive outlook on the company, concurrent with Barrington also raising its price target to $21 and maintaining an Outperform rating. These analyst updates follow Anika Therapeutics' recent earnings report and revised guidance for the fiscal years 2026 and 2027.
